Integrated Microbiome and Metabolomic Profiling to Identify Potential Biomarkers of Major Depressive Disorder.

MDD patients showed distinct taxonomic shifts characterized by enrichment of the Eubacterium eligens group and Veillonella compared to controls.

• Taxonomic profiling was performed using 16S rRNA gene sequencing in a Korean cohort (n = 69).
• Both Eubacterium eligens group and Veillonella were specifically enriched in MDD patients.
• These taxa were identified as the key discriminating microbial features between MDD patients and controls.

Integrated correlation analysis revealed a functional 'gut-lipid axis' in MDD, linking gut dysbiosis to alterations in host acylcarnitine and fatty acid metabolism.

• The functional link was identified through integrated multi-omics correlation analysis combining microbiome and metabolomic data.
• The enriched taxa (Eubacterium eligens group and Veillonella) were strongly associated with alterations in acylcarnitine and fatty acid metabolism.
• The relationship between gut microbiota and systemic lipid metabolism was described as a 'gut-lipid axis'.
• This axis was identified as a potential mechanistic pathway underlying MDD pathophysiology.

Plasma metabolic profiling demonstrated superior diagnostic accuracy for MDD compared to gut microbiota profiling.

• Plasma metabolic profile yielded an AUC of 0.862 for MDD diagnosis.
• Gut microbiota profiling yielded a lower AUC of 0.654 for MDD diagnosis.
• Plasma metabolomics was assessed using both GC-MS analysis and UPLC-QTOF-MS profiling.
• The authors concluded that the circulating metabolome serves as a 'more robust, proximal diagnostic readout for MDD.'

The study employed an integrated multi-omics approach combining gut microbiome and metabolomic profiling in a Korean cohort.

• The study cohort consisted of n = 69 Korean participants.
• Methods included 16S rRNA gene sequencing for microbiome profiling, GC-MS analysis of both urine and plasma, and UPLC-QTOF-MS profiling of plasma.
• The multi-omics approach was designed to address the largely obscure functional link between gut dysbiosis and systemic metabolism in MDD.

The gut microbiome was identified as providing mechanistic insights into lipid dysregulation in MDD rather than serving as the most direct diagnostic marker.

• While gut microbiota profiling had a diagnostic AUC of 0.654, it was considered informative for understanding disease mechanisms.
• The authors concluded that gut microbiome data provides 'mechanistic insights into lipid dysregulation' in MDD.
• The circulating metabolome was characterized as a more proximal diagnostic readout compared to microbiome data.